About Rodin

Team

Management

President & Chief Executive Officer – Adam Rosenberg

Adam Rosenberg joined Rodin in September 2015 as President and Chief Executive Officer. Adam previously co-founded a number of innovative companies in the Boston/Cambridge area, including:

  • Teleos Therapeutics, a biotechnology company leveraging unique insights in zebrafish chemical biology to discover new treatments for CNS disorders
  • Clean Membranes, a nanomaterials company based on MIT technology
  • Link Medicine, focused on developing novel disease-modifying neurodegenerative treatments
  • Faber Law Group, a boutique business law firm focused on the biotechnology sector

Previously, Adam was a principal with Ovation Capital Partners, and has served as strategic advisor and interim executive to multiple companies in biotechnology and digital health. Adam also advised the production of A Late Quartet, a feature film starring Christopher Walken, Philip Seymour Hoffman and Catherine Keener, centered on a cellist in a world-class string quartet who is diagnosed with Parkinson’s disease. He currently serves on the Board of Directors of Adeo Health Sciences, a venture-backed company focused on enabling the early introduction of allergens for infants.

Acting Chief Medical Officer – Hans Moebius, MD

Hans MoebiusDr. Moebius leads clinical strategy for Rodin. Dr. Moebius has a solid track record in R&D leadership in neurodegenerative diseases, resulting in several successful international NDAs, including memantine (Namenda™). In August 2017, his exemplary achievements in neuroscience and clinical practice of neurology were recognized by his appointment as a Fellow of the American Academy of Neurology (FAAN).

Dr. Moebius has unique knowledge of the clinical landscape when developing HDAC inhibitors for neurological disorders. He most recently served as VP Clinical Research at Forum Pharmaceuticals, a biotechnology company focused on the discovery and development of therapies for brain diseases like schizophrenia, Alzheimer’s disease and Fronto-Temporal Dementia. Dr. Moebius ran clinical development of Forum’s AD and HDAC inhibitor programs. Previously, he served as CMO of TauRx, as Senior Vice President Europe for INC Research, as CMO and Managing Director of Merz Pharmaceuticals, and started his career at Ciba/Novartis. Dr. Moebius is board certified in Neurology and Psychiatry, and holds a PhD in Experimental Pharmacology from Heidelberg University.

VP, Head of Discovery – Magnus Ivarsson, Ph.D

Magnus Ivarsson, Ph.D As VP, Head of Discovery, Dr. Ivarsson is responsible for Rodin’s overall scientific direction and translational strategy as the company moves its highly selective, brain penetrant molecules towards the clinic.

Dr. Ivarsson has become a noted expert on the utilization of EEG and translational biomarkers to drive efficient and successful drug discovery and development. He most recently served as VP, Head of Translational Science at Proteostasis Therapeutics. Previously, Dr. Ivarsson co-led the Translational Science Center for AstraZeneca in Sweden, and assumed roles of increasing responsibility in the electrophysiology and biology groups at Pfizer and Merck. He has led or contributed to groups responsible for the advancement of multiple development candidates and IND / NDA submissions.

Senior Director, CNS Research – Berkley Lynch, Ph.D

Dr. Berkley Lynch has worked in CNS drug discovery for over fifteen years, focusing most recently on neurodegeneration. While at UCB, he lead a team developing assays and targets around both neurodegenerative diseases and epilepsy, and he identified the mechanism of action of the marketed antiepileptic drug levetiracetam. More recently, he was Vice President of Discovery Research at Link Medicine, a startup dedicated to Alzheimer’s and Parkinson’s drug development. Dr. Lynch has also worked at Ariad Pharmaceuticals and Dotmatics Inc.

Board of Directors

Bruce Booth, DPhil, Chairman

Bruce BoothBruce Booth is a partner at Atlas Venture. In addition to Rodin, Bruce is currently chairman of AvroBio, miRagen Therapeutics, Nimbus Therapeutics and Quartet Medicine, and also serves on the boards of Lysosomal Therapeutics, Magenta Therapeutics, Unum Therapeutics, and Zafgen (NASDAQ:ZFGN). He previously served on the boards of past Atlas companies Avila (acquired by Celgene), Padlock (acquired by BMS), Prestwick (acquired by Biovail), Stromedix (acquired by Biogen), and a number of other ventures.

Bruce serves as an advisor in various capacities to UCB, Shire, Pfizer, and Takeda. He also serves on the board of the National Venture Capital Association.

Bruce blogs about biotech and venture capital topics at LifeSciVC.com, which is syndicated on Forbes. He has published numerous scientific papers and has authored various biotech venture capital review articles, including several in Nature Biotechnology.

Prior to joining Atlas in 2005, Bruce was a consultant at McKinsey & Company, as well as an investor for Caxton Health Holdings. As a British Marshall Scholar, Bruce received a D.Phil. (PhD) in molecular immunology from Oxford University. His work focused on the study of HIV and tumor immune responses. He received a BS in biochemistry, summa cum laude, from The Pennsylvania State University.

Bruce enjoys fly fishing, skiing, hiking, and running. He lives in Wellesley, MA with his wife and three wonderful kids.

Kees Been
Kees BeenKees Been is Founder, President and CEO of Lysosomal Therapeutics. Been was formerly the President and CEO of EnVivo Pharmaceuticals, where he led EnVivo for eight years from an early-stage start-up to a respected CNS company with a broad pipeline of NCE drug compounds. He spent four years at Biogen where he directed the Oncology Business Unit which was sold to Idec, and, as Senior Vice President of Business Development.
John W. Creecy

John Creecy is Chief Executive Officer and a Director of Remeditex Ventures after serving as President and Chief Executive Officer of Hunt Petroleum Corporation. Prior to that, John served as Chief Operating Officer of the Hodges Companies, Inc. In addition, for more than 20 years he has served in various board positions within the All Saints Health System in Ft. Worth and UTSouthwestern Medical Center and Baylor Health Systems in Dallas. John currently serves as Chairman of the Baylor Scott White All Saints board in Ft. Worth.

John is a graduate of Texas Tech University with a Bachelor’s Degree in Accounting and holds a Master’s of Science Degree in Tax from the University of North Texas. John is also a former Certified Public Accountant and a member of various business/civic organizations in Dallas.

Jason Hong, Ph.D
Jason is a Principal at Third Point LLC, an event-driven hedge fund based in New York City. At Third Point, he is responsible for public and private investments across all healthcare subsectors. Before joining Third Point, Jason worked at Goldman Sachs, Polygon Investment Partners and Sanford C. Bernstein. Prior to Bernstein, he spent four years at McKinsey & Company, working with global healthcare companies in the areas of business development, post-merger integration and clinical program development. Jason holds a Ph.D. in Chemistry from Harvard University and a B.S. with Honors in Chemistry from the California Institute of Technology.
Adam Rosenberg

Adam Rosenberg joined Rodin in September 2015 as President and Chief Executive Officer. Adam previously co-founded a number of innovative companies in the Boston/Cambridge area, including:

  • Teleos Therapeutics, a biotechnology company leveraging unique insights in zebrafish chemical biology to discover new treatments for CNS disorders
  • Clean Membranes, a nanomaterials company based on MIT technology
  • Link Medicine, focused on developing novel disease-modifying neurodegenerative treatments
  • Faber Law Group, a boutique business law firm focused on the biotechnology sector

Previously, Adam was a principal with Ovation Capital Partners, and has served as strategic advisor and interim executive to multiple companies in biotechnology and digital health. Adam also advised the production of A Late Quartet, a feature film starring Christopher Walken, Philip Seymour Hoffman and Catherine Keener, centered on a cellist in a world-class string quartet who is diagnosed with Parkinson’s disease. He currently serves on the Board of Directors of Adeo Health Sciences, a venture-backed company focused on enabling the early introduction of allergens for infants.

Samantha Singer
Samantha SingerSamantha Singer is the Chief Operating Officer of the Broad Institute, where she oversees the institute’s human resources, finance, facilities, and information technology teams, in addition to the Office of Strategic Alliances and Partnering. Mrs. Singer joined the Broad after building extensive experience in corporate strategy and organizational effectiveness. She most recently served as Vice President for Corporate Strategy and Chief of Staff for the Chief Executive Officer at Biogen Idec. Over her six years at the company, she led corporate strategy efforts and oversaw major operations initiatives abroad. Before her time at Biogen Idec, Mrs. Singer was a management consultant, first in the Health Care Practice Area at the Boston Consulting Group, and then in an independent consulting partnership focused on biotech companies and biomedical research centers. She holds an M.S. in molecular biology from The Rockefeller University and an M.B.A. from Harvard Business School.
Clay Thorp

Clay is an entrepreneur turned venture capitalist. Since 1995, he has co-founded eight companies in the life science arena and co-founded Hatteras in 2000. Since co-founding Hatteras, Clay has been instrumental in building the firm from its origins with a $3 million seed fund to a venture capital partnership that manages over $450 million across five venture funds. Clay has led investments in a range of life science companies, including biopharmaceuticals, medical devices, diagnostics, and research informatics.

Clay currently serves as Executive Chairman of PhaseBio Pharmaceuticals and Chairman of GeneCentric Diagnostics. He is also on the boards of Clearside Biomedical (Nasdaq: CLSD), Lysosomal Therapeutics, Artizan Biosciences and Orig3n. He serves on the Chancellor’s Philanthropic Committee at UNC-Chapel Hill, the Board of Visitors of the Line berger Comprehensive Cancer Center at UNC-Chapel Hill, and on the board of the NC School of Science and Mathematics Foundation. Clay holds a Masters of Public Policy from Harvard University and a B.A. in mathematics and art history from the University of North Carolina at Chapel Hill.

Ben Robbins (Observer)

Ben is a Venture Partner at GV, and a medical resident in psychiatry at Massachusetts General Hospital and McLean Hospital. He co-founded a company to improve drug adherence at a community health center in Boston and a non-profit to operate a school for AIDS orphans in Tanzania.

Ben received his M.D. from Harvard Medical School, MBA from Harvard Business School, and B.A. with honors from Dartmouth College. He has been recognized multiple times for his social impact work, including the Harvard Medical School Dean’s community service award, Harvard Medical School Agents of Change seed grant, Harvard Medical School Master Scholar scholarship, and Harvard Business School Social Enterprise fellowship.

Scientific Advisory Board

Li Huei Tsai, Ph.D

Li Huei TsaiDirector, The Picower Institute for Learning and Memory, Picower Professor of Neuroscience, Department of Brain and Cognitive Sciences, Senior Associate Member, Broad Institute, MIT, Cambridge MA.

Marcelo Wood, Ph.D

Marcelo WoodAssociate Professor, Director, Interdepartmental Neuroscience Program Department of Neurobiology and Behavior Center for the Neurobiology of Learning and Memory University of California, Irvine

Lisa Monteggia, Ph.D

Lisa MonteggiaProfessor in the Department of Neuroscience and holds the Ginny and John Eulich Professorship at UT Southwestern Medical Center

Ed Holson, Ph.D

Ed HolsonDirector of the medicinal chemistry group in the Stanley Center for Psychiatric Research and a director of chemistry in the Chemical Biology Platform at the Broad Institute, MIT

Stephen Haggarty, Ph.D

Stephen HaggartyAssistant Professor of Neurology at Harvard Medical School, an Assistant in Neuroscience at Massachusetts General Hospital’s Center for Human Genetic Research, an Affiliate Faculty member of the Harvard Stem Cell Institute, and the Director of Chemical Neurobiology for the Stanley Center for Psychiatric Research at the Broad Institute

Andre Fischer, Ph.D

Andre FischerDep. For Psychiatry and Psychotherapy University Medical Center German Center for Neurodegenerative Diseases, Göttingen Graduate School for Neurosciences, Biophysics, and Molecular Biosciences

 

 

Chemistry Advisory Board

Martin Jefson Ph.D - Chairman, Chemistry Advisory Board

Martin JefsonMartin Jefson, Ph.D, Chair, joined Pfizer Central Research in 1982, where he spent 27 years, ultimately becoming head of CNS Research. Between 1994 and 2009, more than 40 development candidates were discovered by teams that Dr. Jefson led or managed, including many prototype molecules with novel mechanisms of action. One of these, the nicotinic receptor partial agonist varenicline (Chantix™), is approved worldwide as an aid to smoking cessation. Since leaving Pfizer in 2009, he has worked as a pharmaceutical research consultant, supporting the efforts of several venture capital partnerships and more than 20 biotechnology and pharmaceutical companies. Dr. Jefson was the founding CSO of Rodin, and served in that role through March 2016.

William Greenlee, Ph.D

William Greenlee, PhDWilliam Greenlee, Ph.D began his career in medicinal chemistry at Merck Research Laboratories, and later joined the Schering-Plough Research Institute, where has was VP Chemistry. Since 2011 he has worked as an independent consultant, and he serves on several scientific advisory boards. His career spans over 35 years, and includes contributions to the discovery of enalapril (Vasotec™), lisinopril (Prinivil™), vorapaxar (Zontivity™) as well as the BACE1 inhibitor verubecestat, now in Phase III clinical trials for treatment of Alzheimer’s disease. Dr. Greenlee has been the recipient of numerous honors and awards, including the Alfred Burger Award in Medicinal Chemistry from the American Chemical Society (ACS) in 2004. He was inducted into the ACS Medicinal Chemistry Hall of Fame in 2006, was elected a Fellow of the ACS in 2009, has co-authored over 200 research papers, and is an inventor on over 80 issued U.S. patents.

John Lowe, Ph.D

John Lowe, PhDJohn Lowe, Ph.D worked in the antibiotics, anti-inflammatory and CNS groups during his 30-year career at Pfizer. Notable accomplishments include his contributions to the discovery of the atypical antipsychotic drug ziprasidone, marketed as Geodon™ in the US, and to the discovery of the first non-peptide substance P (NK1) receptor antagonist. Dr. Lowe left Pfizer in 2009 and founded JL3Pharma LLC, a consulting company for the pharmaceutical industry. He has authored over 90 publications, presented 15 talks and posters at chemistry and pharmacology meetings, and is an inventor or co-inventor on over 60 patents. For his discovery of the drug Geodon™, Dr. Lowe was awarded the 2005 Northeast Regional Industrial Innovation Award, and the 2007 ACS Heroes of Chemistry Award. He is the 2011 winner of the ACS Award in Industrial Chemistry.

John McCall, Ph.D

John McCall, PhDJohn McCall, Ph.D was Director of CNS Research and then VP, Global Head of Chemistry for Upjohn, and VP Research with Pfizer. During his career, he has worked with different acute and chronic neurologic disorders, psychiatric diseases, neuromuscular disease, cardiovascular disease, inflammatory disease, and oncology. Since 2004, Dr. McCall has managed his own consulting and research company, focused primarily on less prevalent neurological diseases. He co-founded and is Chairman of ReveraGen BioPharma, a company focused on Duchenne Muscular Dystrophy with a candidate molecule currently in Phase 2 clinical development. He is currently a member of the NIH Blueprint and the NIH NeuroNEXT Steering Committees, and serves on multiple scientific advisory boards. He holds 65 US patents and has 78 refereed publications.

Neil Moss, Ph.D

Neil Moss, PhDNeil Moss, Ph.D operates Drug Discovery Solutions, a medicinal chemistry and drug discovery consulting business. During Dr. Moss’s 23 years at Boehringer Ingelheim, he worked on and advanced candidates in multiple therapeutic areas, including CNS, immunology & inflammation, respiratory, cardio-metabolic and virology. Dr. Moss has led projects covering a range of molecular targets, such as kinases, proteases, GPCRs, ion channels, enzymes, nuclear receptors, and protein-protein association, and deployed multiple drug discovery approaches, such as structure-based design, fragment-based drug discovery, high throughput screening lead identification and optimization, and literature to lead.